{
    "clinical_study": {
        "@rank": "137975", 
        "arm_group": [
            {
                "arm_group_label": "Mouth Rinse Administration", 
                "arm_group_type": "Other", 
                "description": "Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations."
            }, 
            {
                "arm_group_label": "Dental Tray Gel Administration", 
                "arm_group_type": "Other", 
                "description": "Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations."
            }, 
            {
                "arm_group_label": "Electric Toothbrush Gel Application", 
                "arm_group_type": "Other", 
                "description": "Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations."
            }, 
            {
                "arm_group_label": "Manual Toothbrush Gel Application", 
                "arm_group_type": "Other", 
                "description": "Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations."
            }
        ], 
        "brief_summary": {
            "textblock": "The focus of the study is to evaluate the safety of multiple study drug administrations and\n      the study drug selectively reducing or eliminating a specific bacteria in the mouth.  It\n      will compare a liquid and gel product applied in different modes."
        }, 
        "brief_title": "Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dental Caries", 
        "condition_browse": {
            "mesh_term": "Dental Caries"
        }, 
        "detailed_description": {
            "textblock": "The study will evaluate the safety of multiple study drug administrations as assessed by\n      adverse event monitoring, oral cavity assessments, targeted physical exams and vital signs.\n      The study will also assess the study drug's ability to selectively reduce or eliminate\n      specific bacteria in the mouth by comparing a liquid and gel product applied in different\n      modes, such as mouth rinse administration and gel application using a dental tray, electric\n      toothbrush or manual toothbrush administered over 7 consecutive days. Subjects will be\n      followed for approximately 8 days after the last study drug administration for safety and\n      microbiology."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects are eligible to participate if they meet the following criteria:\n\n          -  Males and females, 18-75 years of age, inclusive, at the time the Informed Consent\n             Form is signed\n\n          -  Females who are not of childbearing potential defined as postmenopausal with no\n             menstrual periods for 1 year, surgically sterilized (e.g. tubal ligation, Essure\n             procedure, endometrial ablation, or hysterectomy) and have a negative urine pregnancy\n             test at Screening (Visit 1) and Baseline (Visit 2/Day 0) prior to study drug\n             administration\n\n          -  Healthy, as determined by the Investigator (in consultation with the Medical Monitor,\n             as needed),  based on medical and dental history, laboratory results, concomitant\n             medications, oral cavity assessment, and targeted physical examination (extraoral,\n             head and neck) during Screening\n\n          -  Have a minimum of 24 natural teeth without restorations, facings or crowns (excluding\n             third molars) present\n\n          -  Demonstrated ability to expectorate \u22652 mL of stimulated saliva in 5 minutes\n\n          -  Demonstrated ability to swish 10 mL of water for 4 minutes\n\n          -  Male subjects only: willing to use contraception or abstain from sexual activity\n             during the entire study\n\n          -  Have a salivary and dental plaque S. mutans of 2.0 x 10^4  CFUs/mL or greater at\n             Screening using MSB agar plating\n\n          -  Willing to refrain from using non-study dentifrice and other non-study oral care\n             products during the study\n\n          -  Willing to postpone elective dental procedures (e.g. dental cleanings) between\n             Screening and final post-treatment visit (End of Study or Early Termination)\n\n          -  Able to understand and sign the Informed Consent Form prior to initiation of study\n             procedures\n\n          -  Able to communicate with the Investigator/study site personnel, understand and comply\n             with the study requirements, and willing to return for protocol-specified visits at\n             the appointed times\n\n        Exclusion Criteria:\n\n        Subjects are excluded from participation if any of the following apply:\n\n          -  Advanced periodontal disease\n\n          -  Active caries lesion(s) within 30 days prior to study drug administration Note:\n             Subjects will be evaluated for active caries lesions by a visual oral examination. If\n             there is reasonable suspicion for caries in an interstitial area that is not visible\n             by clinical evaluation, radiographs will be performed.\n\n          -  Medical condition (e.g., artificial heart valve, history of infective endocarditis,\n             cardiac transplant with valvular dysfunction, congenital heart disease or total joint\n             replacement) for which antibiotics are recommended prior to dental visits and/or\n             procedures\n\n          -  Pathologic lesions of the oral cavity (suspicious or confirmed)\n\n          -  Full or partial dentures, or orthodontic appliances, e.g. night guards, permanent\n             retainers\n\n          -  Impaired salivary function (unable to provide 2 mL of stimulated saliva within 5\n             minutes)\n\n          -  Use of antibiotics (systemic or topical) or use of other drugs, such as steroids\n             which, in the opinion of the Investigator could influence the study outcome, within\n             30 days prior to Screening\n\n          -  Medical history indicating the woman is of childbearing potential, pregnant,\n             breastfeeding/lactating or she has a positive urine pregnancy test\n\n          -  Participation in a clinical trial or receipt of a non-FDA approved therapy within 30\n             days prior to study drug administration (depending on the specifics, participation in\n             an observational study is not necessarily excluded)\n\n          -  Presence of any condition or concurrent illness, which in the opinion of the\n             Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid\n             arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of\n             study dentifrice and oral care products, or interfere with the ability to comply with\n             study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044081", 
            "org_study_id": "C3J13-201-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Mouth Rinse Administration", 
                    "Dental Tray Gel Administration", 
                    "Electric Toothbrush Gel Application", 
                    "Manual Toothbrush Gel Application"
                ], 
                "description": "Active gel concentrations are 3.2 mg/mL C16G2, active rinses are 1.6 mg/mL C16G2. Placebo is vehicle without C16G2", 
                "intervention_name": "C16G2", 
                "intervention_type": "Drug", 
                "other_name": [
                    "C16G2 Rinse or placebo", 
                    "C16G2 Gel or placebo"
                ]
            }, 
            {
                "arm_group_label": [
                    "Mouth Rinse Administration", 
                    "Dental Tray Gel Administration", 
                    "Electric Toothbrush Gel Application", 
                    "Manual Toothbrush Gel Application"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "mailto:dedwards@jbrutah.com", 
                "last_name": "Debbie Edwards", 
                "phone": "801-261-2000"
            }, 
            "contact_backup": {
                "email": "mailto:levans@jbrutah.com", 
                "last_name": "Lorlie Evans", 
                "phone": "801-261-2000"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84124"
                }, 
                "name": "Jean Brown Research"
            }, 
            "investigator": {
                "last_name": "Adam Marberger, DDS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel and/or Mouth Rinse Doses to Healthy Adult Subjects", 
        "overall_contact": {
            "email": "srogy@c3-jian.com", 
            "last_name": "Siegfried Rogy, PhD", 
            "phone": "310-665-2928", 
            "phone_ext": "232"
        }, 
        "overall_official": {
            "affiliation": "Jean Brown Research", 
            "last_name": "Adam Marberger, DDS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be assessed by comparing the incidence and duration of adverse  events, clinically significant changes in vital signs, oral cavity assessments and targeted physical exams (C16G2 subjects in the four study arms vs. placebo).", 
            "measure": "To evaluate the safety of multiple C16G2 Gel and/or C16G2 Rinse administrations in healthy adult subjects.", 
            "safety_issue": "No", 
            "time_frame": "Screening, Baseline, Days 1-7, & Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Saliva and dental plaque samples will be assessed at screening and Days 1, 7 and 14 for S. mutans (C16G2 subjects in the four study arms vs. placebo).", 
                "measure": "To assess the targeted antimicrobial activity of C16G2 gel and rinse applications as measured by a reduction of dental plaque and salivary Streptococcus mutans (S. mutans).", 
                "safety_issue": "No", 
                "time_frame": "Screening, Baseline, Days 1, 7 & 14"
            }, 
            {
                "description": "Total bacteria will be assessed at screening, baseline and Days 1, 7 and 14 (C16G2 subjects in the four study arms vs. placebo).", 
                "measure": "To assess total bacteria in dental plaque and saliva post-study drug. administration", 
                "safety_issue": "No", 
                "time_frame": "Screening, Baseline, Days 1, 7 & 14"
            }
        ], 
        "source": "C3 Jian, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "C3 Jian, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}